Study on the effectiveness and safety of sitagliptin and metformin in patients with type 2 diabetes

Objective To evaluate the efficacy and safety of combined sitagliptin and metformin in patients with type 2 diabetes treatment for newly diagnosed.Methods Select 140 patients with type 2 diabetes,and randomly divided into two groups,70 cases each.Which team USES the west Craig dean and metformin combination therapy,the control group only treated with metformin.Treatment after 3 months observation of two groups of patients before and after the treatment of fasting plasma glucose(FPG),postprandial blood sugar(PPG),glycosylated hemoglobin(HbAlc),triglycerides(TG),cholesterol(TC),high-density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),the indexes of liver and kidney function,routine urine and electrocardiogram(ecg) changes and adverse reactions of drugs.Results Two groups of patients with FPG,PPG and HbAlc than before treatment significantly decreased,but the team down significantly compared with control group,the difference had statistical significance(P 0.05).3 months after treatment the two groups of adverse reactions mainly gastrointestinal tract reaction,liver and kidney damage,the team weight compared with before treatment in patients with increasing trend,but there was no statistically significant difference(t = 2.01,P 2.01).The incidence of adverse reactions similar between the two groups has no statistical significance(P 0.05).Conclusion Sitagliptin and metformin is safe and effective to improve the fasting blood glucose and HbAlc.